Bruno Paiva

Research interests

Publications

• International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma

  Journal of Clinical Oncology · 2025 · https://doi.org/10.1200/jco-24-01893

• Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report

  Blood Cancer Journal · 2021 · https://doi.org/10.1038/s41408-021-00408-4

• Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage

  Blood Cancer Journal · 2021 · https://doi.org/10.1038/s41408-021-00587-0

• A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma

  Blood Advances · 2020 · https://doi.org/10.1182/bloodadvances.2020002827

• Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.19.01231

• Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel

  Journal of Hematology & Oncology · 2018 · https://doi.org/10.1186/s13045-017-0549-1

• Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma

  Nature Medicine · 2018 · https://doi.org/10.1038/s41591-018-0269-2

• Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2016.69.2517

• Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment

  Cancer Cell · 2017 · https://doi.org/10.1016/j.ccell.2017.02.002

• Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

  Leukemia · 2017 · https://doi.org/10.1038/leu.2017.29

• International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30206-6

• Whole-genome fingerprint of the DNA methylome during human B cell differentiation

  Nature Genetics · 2015 · https://doi.org/10.1038/ng.3291

• International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)70442-5

• Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

  Blood · 2014 · https://doi.org/10.1182/blood-2014-01-550020

• Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

  New England Journal of Medicine · 2013 · https://doi.org/10.1056/nejmoa1300439

• MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia

  Leukemia · 2013 · https://doi.org/10.1038/leu.2013.62

• High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

  Blood · 2011 · https://doi.org/10.1182/blood-2011-07-370460

• Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

  The Lancet Oncology · 2010 · https://doi.org/10.1016/s1470-2045(10)70187-x

• Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

  Blood · 2008 · https://doi.org/10.1182/blood-2008-05-159624

Current projects

No projects listed.